Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

被引：20

作者：

Morgan, Gareth ^{[1
]}

Palumbo, Antonio ^{[2
]}

Dhanasiri, Sujith ^{[3
]}

Lee, Dawn ^{[4
]}

Weisel, Katja ^{[5
]}

Facon, Thierry ^{[6
]}

Delforge, Michel ^{[7
]}

Oriol, Albert ^{[8
]}

Zaki, Mohamed ^{[9
]}

Yu, Xin ^{[9
]}

Sternas, Lars ^{[9
]}

Jacques, Christian ^{[9
]}

Akehurst, Ron ^{[4
,10
]}

Offner, Fritz ^{[11
]}

Dimopoulos, Meletios A. ^{[12
]}

机构：

[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA

[2] Via Univ Torino, Turin, Italy

[3] Celgene Ltd, London, England

[4] Bres Med, Sheffield, S Yorkshire, England

[5] Univ Tubingen, Tubingen, Germany

[6] CHU Lille, Serv Malad Sang, F-59037 Lille, France

[7] Univ Hosp Leuven, Leuven, Belgium

[8] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[9] Celgene Corp, Summit, NJ USA

[10] Univ Sheffield, Sheffield, S Yorkshire, England

[11] Univ Ziekenhuis Gent, Ghent, Belgium

[12] Univ Athens, Alexandra Hosp, Sch Med, Athens 11528, Greece

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2015年 / 168卷 / 06期

关键词：

multiple myeloma; pomalidomide; survival; crossover; bias;

D O I：

10.1111/bjh.13227

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the phase III MM-003 trial, pomalidomide plus low-dose dexamethasone (POM+LoDEX) improved overall survival (OS) versus high-dose dexamethasone (HiDEX) in 455 patients with relapsed and refractory multiple myeloma (RRMM) after treatment with bortezomib and lenalidomide. Here, a two-stage Weibull method was used to adjust for the crossover of patients in the HiDEX arm to pomalidomide-based therapy. The adjusted difference in median OS between patients in the POM+LoDEX and HiDEX arms was 70months (127 vs. 57months, respectively). These findings provide important evidence for understanding the clinical efficacy of pomalidomide on OS benefits seen in RRMM patients.

引用

页码：820 / 823

页数：4

共 50 条

[41] MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)
Richardson, Paul G.
Hofmeister, Craig C.
Siegel, David
Lonial, Sagar
Laubach, Jacob P.
Efebera, Yvonne A.
Vesole, David H.
Nooka, Ajay K.
Rosenblatt, Jacalyn
Raje, Noopur
Zaki, Mohamed H.
Hua, Ye
Li, Yan
Shah, Sheetal
Wang, Jianming
Anderson, Kenneth C.
[J]. BLOOD, 2013, 122 (21)
[42] MM-005: A PHASE 1 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Richardson, P.
Hofmeister, C.
Siegel, D.
Lonial, S.
Laubach, J.
Efebera, Y.
Vesole, D.
Nooka, A.
Rosenblatt, J.
Raje, N.
Zaki, M.
Hua, Y.
Shah, S.
Wang, J.
Anderson, K.
[J]. HAEMATOLOGICA, 2013, 98 : 97 - 98
[43] Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment
Siegel, David S.
Weisel, Katja C.
Dimopoulos, Meletios A.
Baz, Rachid
Richardson, Paul G.
Delforge, Michel
Song, Kevin
San Miguel, Jesus
Moreau, Philippe
Yu, Xin
Hong, Kevin
Sternas, Lars
Zaki, Mohamed H.
Palumbo, Antonio
[J]. BLOOD, 2015, 126 (23)
[44] MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM)
Richardson, Paul Gerard Guy
Hofmeister, Craig C.
Siegel, David Samuel DiCapua
Lonial, Sagar
Laubach, Jacob
Efebera, Yvonne Adeduni
Vesole, David H.
Nooka, Ajay K.
Rosenblatt, Jacalyn
Raje, Noopur S.
Zaki, Mohamed H.
Hua, Ye
Shah, Sheetal
Wang, Jianming
Anderson, Kenneth Carl
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[45] Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis
Moreau, Philippe
Dimopoulos, Meletios A.
Richardson, Paul G.
Siegel, David S.
Cavo, Michele
Corradini, Paolo
Weisel, Katja
Delforge, Michel
O'Gorman, Peter
Song, Kevin
Chen, Christine
Bahlis, Nizar
Oriol, Albert
Hansson, Markus
Kaiser, Martin
Anttila, Pekka
Raymakers, Reinier
Joao, Cristina
Cook, Gordon
Sternas, Lars
Biyukov, Tsvetan
Slaughter, Ana
Hong, Kevin
Herring, Jennifer
Yu, Xin
Zaki, Mohamed
San-Miguel, Jesus
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (03) : 199 - 206
[46] Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study
Terpos, Evangelos
Repousis, Panagiotis
Lalayanni, Chrysavgi
Hatjiharissi, Evdoxia
Assimakopoulou, Theodora
Vassilopoulos, Georgios
Pouli, Anastasia
Spanoudakis, Emmanouil
Michalis, Eurydiki
Pangalis, Gerassimos
Ntanasis-Stathopoulos, Ioannis
Poziopoulos, Christos
Kyrtsonis, Marie-Christine
Pappa, Vasiliki
Symeonidis, Argiris
Georgopoulos, Christos
Zikos, Panagiotis M.
Gavriatopoulou, Maria
Papadaki, Helen A.
Dadakaridou, Magdalini
Karvounis-Marolachakis, Kiki
Katodritou, Eirini
[J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (07)
[47] POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: PHASE 1 PHARMACOKINETICS AND SAFETY
Matous, J.
Siegel, D.
Lonial, S.
Harvey, R. D.
Kasserra, C.
Li, Y.
Chen, M.
Doerr, T.
Sternas, L.
Zaki, M.
Jacques, C.
Shah, J.
[J]. HAEMATOLOGICA, 2015, 100 : 507 - 508
[48] A PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: THE MM-011 TRIAL
Hagiwara, S.
Okamoto, S.
Matsue, K.
Iida, S.
Sunami, K.
Komeno, T.
Suzuki, K.
Ando, K.
Taniwaki, M.
Tobinai, K.
Chou, T.
Kaneko, H.
Iwasaki, H.
Uemura, C.
Tamakoshi, H.
Zaki, M. H.
Doerr, T.
Kuroda, Y.
Ichinohe, T.
[J]. HAEMATOLOGICA, 2016, 101 : 790 - 790
[49] Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
Dimopoulos, Meletios A.
Weisel, Katja
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Moreau, Philippe
Banos, Anne
Oriol, Albert
Garderet, Laurent
Cavo, Michele
Ivanova, Valentina
Alegre, Adrian
Lopez, Joaquin Martinez
Chen, Christine I.
Spencer, Andrew
Knop, Stefan
Bahlis, Nizar J.
Renner, Christoph
Yu, Xin
Hong, Kevin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
San Miguel, Jesus F.
[J]. BLOOD, 2013, 122 (21)
[50] ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma Final Overall Survival Analysis
Raab, Marc-Steffen
Dimopoulos, Meletios
Dytfeld, Dominik
Grosicki, Sebastian
Moreau, Philippe
Takezako, Naoki
Hori, Mitsuo
Leleu, Xavier
Leblanc, Richard
Suzuki, Kenshi
Richardson, Paul G.
Mckiver, Mihaela Popa
Jou, Ying-Ming
Yao, David
Das, Prianka
San-Miguel, Jesus
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 174 - 174

← 1 2 3 4 5 →